SGLT-2 inhibition in IgA nephropathy: the new standard of care?
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 33878337.
- Also identified by DOI 10.1016/j.kint.2021.04.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.
Medical subject headings
- Glomerulonephritis, IGA
- Renal Insufficiency, Chronic